Physician profile

Cyril Abrams

Cardiovascular Disease · Jacksonville, NC

NPI 1821098344

$5,659.20

in general payments reported to CMS, 2019-2025

40 companies · $395 in 2025

The $395 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,222.88

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $871.00 2022-2025
Amgen INC. $607.16 2019-2025 Repatha, Otezla
Astrazeneca Pharmaceuticals Lp $490.34 2019-2024 Farxiga
Janssen Pharmaceuticals, INC $447.39 2019-2024 Xarelto
Novo Nordisk INC $335.23 2019-2025
Bayer Healthcare Pharmaceuticals INC. $273.86 2021-2022
E.R. Squibb & Sons, L.L.C. $260.08 2022-2025 Camzyos, Eliquis
Lilly USA, LLC $231.59 2019-2025 Mounjaro, Zepbound
Pfizer INC. $181.53 2021-2025
Preventric Diagnostics, INC. $173.52 2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $150.31 2019-2021
Abbott Laboratories $148.10 2019-2024 Mitraclip, Amplatzer Amulet, Freestyle Libre 3
Genzyme Corporation $140.19 2019-2024
Daiichi Sankyo INC. $105.80 2022-2024 Injectafer
Philips North America LLC $102.01 2022-2024 (5050) Extended Holter, (Ck7) Extended Holter
Show all 40 companies
CompanyGeneral paymentsYearsTop products
Irhythm Technologies, INC. $98.85 2022-2024 Zio Xt Patch, Zio Monitor
Boehringer Ingelheim Pharmaceuticals, INC. $98.10 2019-2024 Jardiance
Grifols USA, LLC $97.91 2019-2020
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $96.59 2021-2025 Lifevest
Medtronic, INC. $87.50 2022-2023 Intellis Adaptivestim
Arbor Pharmaceuticals, INC. $79.78 2019-2020
Neurocrine Biosciences, INC. $79.62 2022
Alnylam Pharmaceuticals INC. $70.94 2022-2023 Onpattro
Amarin Pharma, INC. $53.20 2021
Lexicon Pharmaceuticals, INC. $46.13 2023 Inpefa
Kiniksa Pharmaceuticals, Ltd. $42.81 2023 Arcalyst
Inspire Medical Systems, INC. $32.93 2023 Inspire
Edwards Lifesciences Corporation $32.51 2022-2023 Edwards Sapien 3 Ultra Transcatheter Heart Valve
Merck Sharp & Dohme LLC $30.72 2019-2024 Gardasil 9, Gardasil, Capvaxive
Kowa Pharmaceuticals America, INC. $25.48 2019-2020
Vital Connect, INC $22.94 2025 Vitalpatch Rtm
Kiniksa Pharmaceuticals International, Plc $22.78 2024 Arcalyst
Esperion Therapeutics, INC. $20.47 2024 Nexletol
Abbvie INC. $17.91 2024
Astellas Pharma US INC $17.38 2024 Veozah
Glaxosmithkline, LLC. $14.68 2025 Arexvy
Paratek Pharmaceuticals, INC. $14.54 2022
Intercept Pharmaceuticals, INC. $14.53 2019
Ironwood Pharmaceuticals, INC $11.83 2020
Ironshore Pharmaceuticals INC. $10.96 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Cyril Abrams

$5,659.20

in general payments reported 2019-2025

Years
2019-2025
Top company
Novartis Pharmaceuticals Corporation
Context
The $395 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/443859/cyril-abrams

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.